Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients

José Antonio Mata-Marín,Ariane Estrella Weiser Smeke,Mariana Rotzinger Rodriguez,Marcelino Chávez-García,Marco Isaac Banda-Lara,Alma Minerva Pérez Rios,Nohemí Nuñez-Rodríguez,Juan Carlos Domínguez-Hermosillo,Alberto Chaparro-Sánchez,Irene Juarez-Kasusky,Javier Enrique Cruz Herrera,Jorge Luis Sandoval-Ramírez,Jesús Gaytán Martínez

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients

2017

José Antonio Mata-Marín
Ariane Estrella Weiser Smeke
Mariana Rotzinger Rodriguez
Marcelino Chávez-García
Marco Isaac Banda-Lara
Alma Minerva Pérez Rios
Nohemí Nuñez-Rodríguez
Juan Carlos Domínguez-Hermosillo
Alberto Chaparro-Sánchez
Irene Juarez-Kasusky
Javier Enrique Cruz Herrera
Jorge Luis Sandoval-Ramírez
Jesús Gaytán Martínez

Objective We evaluated the effectiveness of a raltegravir (RAL)-containing regimen plus an optimized background regimen in HIV-1 highly treatment-experienced patients.

Keywords:

Raltegravir Potassium
Diabetes mellitus
Raltegravir
Medicine
Regimen
Pharmacology
Virology
Retrospective cohort study
Cohort study
Internal medicine
Cohort
Viral load
Odds ratio

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations